Daewon Pharmaceutical Reports Phase 3 Non-Inferiority for DW4421
Daewon Pharmaceutical said its DW4421 (faprazan) Phase 3 trial for erosive gastroesophageal reflux disease demonstrated non-inferiority to esomeprazole.
Related stories
HSBC raises GE Vernova to Buy from Hold
M impact | EQUITY | Oct 30, 2026, 06:19 AM UTC
ResMed Publishes Q1 FY2027 Earnings Call Transcript
ResMed published a transcript of its Q1 fiscal 2027 earnings call.
M impact | EQUITY | Oct 30, 2026, 06:15 AM UTC
Microsoft Prices $25 Billion Senior Unsecured Notes Offering
Microsoft announced pricing for $25 billion in aggregate principal amount of senior unsecured notes.
H impact | EQUITY | Oct 30, 2026, 06:12 AM UTC
Asian session market picture: S&P 500 -0.93%, Nasdaq 100 -2%; USD/JPY -0.01%, WTI +1.32%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.93 percent, Nasdaq futures is down 2 percent, Dow futures is down 0.15 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 06:00 AM UTC
Strategy Eyes More Bitcoin Buys, Cites $30 Billion Credit Capacity
Strategy is looking to finance additional Bitcoin purchases through preferred-share offerings. Executive Chairman Michael Saylor said the company has capacity to create up to $30 b
M impact | EQUITY | Oct 30, 2026, 05:56 AM UTC
Technip Energies Flags Hormuz Logistics Risk to Middle East Projects in 2027
M impact | EQUITY | Oct 30, 2026, 05:55 AM UTC